McRae-Clark Aimee L, Carter Rickey E, Killeen Therese K, Carpenter Matthew J, Wahlquist Amy E, Simpson Stacey A, Brady Kathleen T
Department of Psychiatry, Medical University of South Carolina, 67 President Street, Charleston, SC 29425, USA.
Drug Alcohol Depend. 2009 Nov 1;105(1-2):132-8. doi: 10.1016/j.drugalcdep.2009.06.022. Epub 2009 Aug 21.
The present study investigated the potential efficacy of buspirone for treating marijuana dependence. Participants received either buspirone (maximum 60mg/day) (n=23) or matching placebo (n=27) for 12 weeks, each in conjunction with motivational interviewing. In the modified intention-to-treat analysis, the percentage of negative UDS results in the buspirone-treatment group was 18 percentage points higher than the placebo-treatment group (95% CI: -2% to 37%, p=0.071). On self-report, participants receiving buspirone reported not using marijuana 45.2% of days and participants receiving placebo reported not using 51.4% of days (p=0.55). An analysis of participants that completed the 12-week trial showed a significant difference in the percentage negative UDS (95% CI: 7-63%, p=0.014) and a trend for participants randomized to the buspirone-treatment group who completed treatment to achieve the first negative UDS result sooner than those participants treated with placebo (p=0.054). Further study with buspirone in this population may be warranted; however, strategies to enhance study retention and improve outcome measurement should be considered in future trials.
本研究调查了丁螺环酮治疗大麻依赖的潜在疗效。参与者接受丁螺环酮（最大剂量60mg/天）（n = 23）或匹配的安慰剂（n = 27）治疗12周，每组均结合动机性访谈。在改良意向性分析中，丁螺环酮治疗组的尿毒品检测阴性结果百分比比安慰剂治疗组高18个百分点（95%置信区间：-2%至37%，p = 0.071）。自我报告显示，接受丁螺环酮治疗的参与者报告有45.2%的日子未使用大麻，接受安慰剂治疗的参与者报告有51.4%的日子未使用大麻（p = 0.55）。对完成12周试验的参与者进行的分析显示，尿毒品检测阴性百分比存在显著差异（95%置信区间：7 - 63%，p = 0.014），并且随机分配到丁螺环酮治疗组且完成治疗的参与者比接受安慰剂治疗的参与者更早获得首次尿毒品检测阴性结果，存在一定趋势（p = 0.054）。可能有必要对该人群进一步开展丁螺环酮研究；然而，未来试验应考虑提高研究保留率和改善结果测量的策略。
